1. Герасимова Е.Н. Альдостерон в клинике внутренних болезней. Кардиология. 1961; 3: 92–4.
2. Simpson SA, Tait JF, Bush IE. Secretion of a salt-retainig hormone by the mammalian adrenal cortex. The Lancet 1952; 260 (6727): 226–8.
3. Slater JDH. Aldosterone antagonism by 17-Spirolactosteroids. Postgrad Med J 1960; 36 (416): 399–407.
4. Hutchinson JH, Porte GA. Spirolactone inhibition of aldosterone induced nuclear RNA synthesis in toad urinary bladder. Res Comm Chem Path Pharm 1970; 1 (3): 363–9.
5. Smith WG. The Lancet 1962; 280 (7261): 886.
6. Мухарлямов Н.А., Мареев В.Ю. Лечение хронической сердечной недостаточности. М., 1985.
7. Borghi С, Ambrosioni E. Clinical aspects of ACE inhibition in patients with acute myocardial infarction. Cardiovasc Drugs Ther 1996; 10 (3): 519–25.
8. The Merit Study Group. The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000; 283 (10): 1295–302.
9. Pitt B. «Escape» of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995; 9 (4): 145–9.
10. Borghi C et al. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993; 33 (9): 40–5.
11. Weber KT, Villarreal D, Griffing GT. Heart Failure: Pathophysiology, Aldosterone and Anti-aldosterone therapy. GD Searle & Co 1993.
12. The CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730–6.
13. Selye H. Protection by a steroid-spirolactone against certain types of cardiac necroses. Proc Soc Exp Biol Med 1960; 104 (7): 212–3.
14. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78 (11): 902–7.
15. Bertram P et al. for The randomized aldactone evaluation study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341 (10): 709–17.
16. Maron BA, Leopold JA. Aldosterone receptor antagonists: effective but often forgotten. Circulation 2010; 121 (7): 934–9.
17. Pitt B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348 (14): 1309–21.
18. Pitt B, White H, Nicolau J et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46 (3): 425–31.
19. Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364 (1): 11–21.
20. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787–847.
Авторы
Д.А.Андреев
Кафедра профилактической и неотложной кардиологии ФППОВ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ